These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 38985839

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ, Kim H, Shin K, Hong TH, Suh JH, Lee MA.
    BMC Cancer; 2021 Nov 03; 21(1):1176. PubMed ID: 34732161
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
    Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT.
    Eur J Cancer; 2019 Feb 03; 108():78-87. PubMed ID: 30654298
    [Abstract] [Full Text] [Related]

  • 5. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
    Glassman DC, Palmaira RL, Covington CM, Desai AM, Ku GY, Li J, Harding JJ, Varghese AM, O'Reilly EM, Yu KH.
    BMC Cancer; 2018 Jun 27; 18(1):693. PubMed ID: 29945562
    [Abstract] [Full Text] [Related]

  • 6. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
    Vogel A, Ciardiello F, Hubner RA, Blanc JF, Carrato A, Yang Y, Patel DA, Ektare V, de Jong FA, Gill S.
    Cancer Treat Rev; 2016 Nov 27; 50():142-147. PubMed ID: 27676174
    [Abstract] [Full Text] [Related]

  • 7. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
    Hubner RA, Cubillo A, Blanc JF, Melisi D, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT.
    Eur J Cancer; 2019 Jan 27; 106():24-33. PubMed ID: 30458340
    [Abstract] [Full Text] [Related]

  • 8. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A.
    Eur J Cancer; 2021 Jul 27; 151():14-24. PubMed ID: 33957442
    [Abstract] [Full Text] [Related]

  • 9. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
    Park HS, Kang B, Chon HJ, Im HS, Lee CK, Kim I, Kang MJ, Hwang JE, Bae WK, Cheon J, Park JO, Hong JY, Kang JH, Kim JH, Lim SH, Kim JW, Kim JW, Yoo C, Choi HJ.
    ESMO Open; 2021 Apr 27; 6(2):100049. PubMed ID: 33578192
    [Abstract] [Full Text] [Related]

  • 10. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
    Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA.
    Eur J Cancer; 2018 Dec 27; 105():71-78. PubMed ID: 30414528
    [Abstract] [Full Text] [Related]

  • 11. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer.
    Tang CY, Yang SH, Li CP, Su YY, Chiu SC, Bai LY, Shan YS, Chen LT, Chuang SC, Chan DC, Yen CJ, Peng CM, Chiu TJ, Chen YY, Chen JS, Chiang NJ, Chou WC.
    Pancreatology; 2024 Jun 27; 24(4):600-607. PubMed ID: 38565467
    [Abstract] [Full Text] [Related]

  • 12. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study.
    Gupta A, De Jesus-Acosta A, Zheng L, Lee V, Kamel I, Le D, Pishvaian M, Laheru D.
    Front Oncol; 2023 Jun 27; 13():1250136. PubMed ID: 37700832
    [Abstract] [Full Text] [Related]

  • 13. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.
    Nagashima S, Kobayashi S, Tsunoda S, Yamachika Y, Tozuka Y, Fukushima T, Morimoto M, Ueno M, Furuse J, Maeda S.
    Int J Clin Oncol; 2024 Feb 27; 29(2):188-194. PubMed ID: 37991558
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis.
    Chen BS, Chan SY, Bteich F, Kuang C, Meyerhardt JA, Ma KS.
    Crit Rev Oncol Hematol; 2024 Sep 27; 201():104386. PubMed ID: 38735505
    [Abstract] [Full Text] [Related]

  • 15. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
    Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, Chen J, de Jong FA.
    J Geriatr Oncol; 2019 May 27; 10(3):427-435. PubMed ID: 30842038
    [Abstract] [Full Text] [Related]

  • 16. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
    Yu HY, Lee CY, Lin LG, Chao Y, Li CP.
    J Chin Med Assoc; 2022 Jan 01; 85(1):42-50. PubMed ID: 34759212
    [Abstract] [Full Text] [Related]

  • 17. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Nichetti F, Rota S, Ambrosini P, Pircher C, Gusmaroli E, Droz Dit Busset M, Pusceddu S, Sposito C, Coppa J, Morano F, Pietrantonio F, Di Bartolomeo M, Mariani L, Mazzaferro V, de Braud F, Niger M.
    JAMA Netw Open; 2024 Jan 02; 7(1):e2350756. PubMed ID: 38190183
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.